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ABSTRACT OF THESIS 
 
 
 
EVALUATION OF RHODOCOCCUS EQUI SUSCEPTIBILITY TO SILVER 
NANOPARTICLE ANTIMICROBIALS 
 
 
Rhodococcus equi is a significant cause of pneumonia in foals and 
immunocompromised humans. Antimicrobial resistance among R. equi isolates has 
developed as a consequence of inappropriate stewardship and bacterial evolution, leading 
to an increased rate of treatment failures that typically result in foal fatality. In the current 
study, we evaluated the efficacy of antimicrobial silver nanoparticle (AgNP) complexes in 
controlling R. equi growth. Previous studies characterizing AgNP-induced antibacterial 
effects in other Gram-positive pathogens led us to hypothesize that silver nanoparticle 
antimicrobials impact R. equi viability and intracellular replication. We therefore 
investigated the effect of silver nanoparticle complexes on R. equi growth; assessed 
whether silver nanoparticle complexes prevent intracellular replication of R. equi; and 
evaluated the safety of silver nanoparticles in host cells. The results presented here 
demonstrate that silver nanoparticle complexes exhibit bactericidal activity against R. equi. 
However, AgNP effective concentrations also induced rapid apoptosis and secondary 
necrosis of macrophage-like cells and equine pulmonary endothelial cells, suggesting 
multiple mechanisms of cytotoxicity. Overall, this study demonstrates that while silver 
nanoparticle-based therapeutics can effectively control R. equi proliferation, application of 
AgNP complexes as a treatment strategy for controlling rhodococcal disease may be 
limited by adverse host cellular effects. 
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CHAPTER 1. LITERATURE REVIEW 
 
 
 
1.1 Introduction 
 
Rhodococcus equi is a non-motile, aerobic Gram-positive nocaridoform 
actinomycetes that is morphologically distinguished by the development of pleomorphic 
coccobacilli and orange-pink, mucoid-like colonies (1-6). R. equi can be isolated from a 
multitude of environments and is one of two pathogenic species within the Rhodococcus 
genus (1, 7-9). Though R. equi has been isolated from both marine and land animals on 
every continent except Antarctica, it is primarily a free-living soil-dwelling bacterium. R. 
equi can opportunistically infect their host via the aerosolization and inhalation of 
contaminated dust particles. In foals, the bacteria preferentially colonize alveolar 
macrophages, leading to the development of bronchopneumonia characterized by 
granulomatous lesions and bacterial-induced tissue necrosis (8-13). 
The greatest risk factors associated with infection and disease spread includes high 
stock density, especially when consisting of a majority of mares and foals, and crowded 
paddocks (8, 14-17). Notably, the occurrence of R. equi geographically differs among 
farms, with some farms developing endemic R. equi disease (15-19). Consequently, farms 
with endemic R. equi encounter high morbidity rates and excess foal wastage associated 
with disease progression to a chronic suppurative bronchopneumonia. In addition to 
respiratory infection, R. equi can also multiply in the intestinal tract following ingestion 
(contributing to a fecal-oral transmission cycle) and can also be acquired through direct 
inoculation of wounds and mucous membranes as well as hematogenous dissemination to 
distant sites. As a result, additional sequalae associated with R. equi colonization includes 
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ulcerative enterocolitis, colonic lymphadenopathy, mesenteric lymphadenopathy, 
typhlocolitis, septic and non-septic arthritis, immune-mediated synovitis and uveitis, and 
osteomyelitis (7, 8, 18). 
The equine industry suffers annual financial distress arising from investments in 
failing treatments against R. equi pneumonia and the subsequent foregone cost associated 
with resulting foal mortalities (16, 19). In addition to the horse industry, R. equi is 
associated with adverse outcomes in other industries (3, 4, 11, 20). For example, R. equi 
is commonly cultured from the submaxillary lymph nodes of pigs with granulomatous 
lymphadenitis and can be isolated from 3-5% of apparently healthy pigs (1, 18, 21). On 
occasion, it can also be isolated from abscesses or granulomas in the lymph nodes in cattle, 
in which it also causes a chronic pyogranulomatous adenitis. In rare cases, R. equi has also 
been isolated from pulmonary and extrapulmonary infections in goats, camelids, dogs and 
cats (1, 7, 20-24). More striking, however, is that R. equi has the capacity to cause fatal 
bronchopneumonia in immunocompromised humans, particularly those infected with 
HIV, and has been observed to cause high-case fatality rates (1, 3, 8-12, 21, 24, 25). 
Though here have been many attempts in generating effective prophylactic and 
therapeutic treatments against R. equi, these have had limited success. Ineffective R. equi 
control thus remains a heavy financial burden on horse breeders and also introduces 
selective pressures that can accelerate the development of antimicrobial resistance (8, 26- 
28). Together, the multi-host and zoonotic potential and increased rates of macrolide 
resistance may present additional challenges in the years to come. Thus, understanding the 
molecular mechanisms underlying R. equi infection will identify disease checkpoints that 
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can be targeted in novel antimicrobial treatment and prevention strategies to benefit both 
veterinary and human medicine (7-9). 
 
 
 
1.2 Epidemiology 
 
R. equi is found ubiquitously within the environment, and has been isolated from 
the air, soil, water, and feces at equine breeding farms, including the feces of week-old 
foals (15, 16, 19). The pathogen can also be isolated from the large intestines of horses and 
presumably spreads via the fecal-oral route as the volatile fatty acids in the fecal matter 
enhances R. equi growth (11, 19, 27). Interestingly, disease primarily occurs at large 
breeding farms that maintain environmental control methods which include rotation of 
animals between different paddocks and reduction of fecal buildup. While these techniques 
can contribute to the control and prevention of contagious disease, there appears to be no 
impact of aseptic management practices to R. equi incidence (18, 29). Instead, disease 
incidence is strongly associated with high equine density that is inclusive of large 
populations of mares and foals (18, 29). These factors are of particular importance when 
horses are housed in stables as R. equi numbers increase per given area when shed via feces 
(28, 30, 31). In some geographic areas, pathogen concentration also increases when 
weather conditions are warmer, drier, and windier as bacterial aerosolization can be 
elevated under conditions of low soil moisture, poor grass cover and high ambient 
temperature (18, 24). However, while exposure to the bacterium is widespread, disease is 
either sporadic or endemic, suggesting that equine genetics play a role in disease severity 
and immunity. In support of an equine genetic basis of rhodococcal disease, anecdotal 
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reports indicate that some mares recurrently produce foals that exhibit a higher 
susceptibility to R. equi disease (16, 19, 27). 
 
 
 
1.3 Molecular Determinants of R. equi Pathogenesis 
 
Although R. equi was first isolated in 1923, relatively little is known about the 
complex molecular mechanisms that drive R. equi pathogenesis (7, 14, 32). R. equi harbors 
a 5.04 Mb circular chromosome and at least one 85-90 kb circular plasmid which has a 
combined GC-content of 68.76% (32-34). The R. equi strain 103S chromosome exhibits a 
low mutation rate, a virtual absence of DNA mobility genes or insertion sequences, and a 
small number of pseudogenes (7). The chromosome contains endogenous antibiotic 
resistance determinants, including 10 b-lactamases which provide resistance to b-lactam 
antibiotics, 5 aminoglycoside phosphotransferases, and 4 multidrug efflux pumps (7, 35). 
The virulence-associated plasmid (pVap), which was presumably acquired via horizontal 
gene transfer (HGT) (1, 36-38), contains 73 coding sequences (CDS) based on predicted 
open reading frames (ORFs). The pVap includes a ~21-kb pathogenicity island (PAI) 
which is essential for virulence in the horse. The PAI consists of 26 ORFs as well as 
numerous hypothetical proteins which appear to be unique to R. equi based on a lack of 
annotated sequence similarity to proteins in other bacterial species (1, 13, 39). 
 
The ability of R. equi to infect macrophages and arrest phagosomal maturation 
ensures protected bacterial proliferation and impairs the host immune response (23, 40, 
41). The capacity to replicate intracellularly has been directly linked to the presence of the 
pVap which encodes a number of virulence-associated proteins (Vaps). The importance of 
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pVap in R. equi pathogenesis is highlighted by experiments demonstrating that plasmid 
curing renders the bacterium avirulent in the foal (8, 14, 23, 25). In the horse-specific strain, 
host survival is associated with the absence of the 15-17 kDA virulence-associated protein 
A gene (vapA) (8, 14, 23, 25). While VapA-positive plasmids infect horses, VapB-positive 
and VapN-positive plasmids (which contain neither vapA nor vapB) infect pigs and cattle, 
respectively. In the case of humans, infection is associated with R. equi harboring either 
VapA-, VapB-, or VapN-type plasmids, though VapB-positive strains are the most 
commonly isolated (1, 13, 21, 23, 40, 42). 
Opsonized R. equi parasitizes macrophages and proliferates within a membrane- 
bound vesicle termed the R. equi containing vacuole (RCV). While the exact mechanism 
of intramacrophage survival is unknown, success of the pathogen depends on the ability to 
prevent phagosomal maturation and inhibit the production of microbicidal compounds 
following phagocytic uptake (10, 12, 43, 44). VapA is a highly immunodominant and 
immunogenic protein that is localized to the cell surface of virulent R. equi strains (25, 39, 
45, 46). Studies have demonstrated that vapA expression is externally modulated by 
temperature and pH, with optimal Vap protein production occurring between 34-41°C and 
pH 5.0 (25, 40, 47). These parameters fall within the environmental conditions encountered 
during early phagolysosome formation following macrophagic uptake (25, 40, 47). Thus, 
phagocytosis of the bacteria is proposed to stimulate virulence. However, the pVapA isn’t 
solely responsible for virulence in the horse as pVapN R. equi has been isolated from sick 
foals (32, 39). While VapA contains lipid-binding properties that may contribute to 
infection and is pH neutralizing, the exact role of VapA in pathogenesis has yet to be fully 
elucidated (10, 23, 32). 
6  
Within the equine-specific strain of R. equi, there are 6 full-length vap genes (A, C, 
D, E, G, H) and 3 truncated pseudogenes (F, I, X) that are encoded within the PAI, but only 
VapA has been shown to have a role in virulence (2, 23, 25). In total, the PAI encodes 20 
ORFs, of which 3 ORFs are required for virulence (47-49). In addition to vapA, a two- 
component system encoded by virR (orf4) and virS (orf8) plays a role in infection (47-49). 
During infection, the VirS sensor kinase responds to external stimuli to activate the VirR 
response regulator. In turn, activated VirR binds to the vapA promotor to stimulate vapA 
expression (7, 47, 49, 50). Additionally, virRS contributes to the expression of 
chromosomally-encoded genes, demonstrating virulence-associated cross-talk between the 
plasmid and the chromosome (11, 39, 40). 
Despite being Gram-positive, R. equi produce an outer cell envelope termed the 
‘Mycobacterial Outer Membrane’ (MOM) (11, 13, 23). The MOM contains mycolic acids 
that form a wax-like outer surface layer that provides a mechanism to protect the bacterium 
from dehydration in the soil environment (7, 39). Additionally, the mycolic acids that 
comprise the outer membrane serve as a virulence trait. For example, R. equi mutants that 
lack the b-ketoacyl-(acyl carrier protein)-synthase A enzyme (KasA) exhibit reduced 
intramacrophagic growth as a result of defective mycolic acid biosynthesis (7, 32, 51). 
Similar to Mycobacterium tuberculosis, R. equi harbors additional chromosomally- 
encoded virulence factors including a Mycobacterial-like aceA-encoded isocitrate lyase 
that is involved in intracellular replication (32, 39, 52). R. equi also encode a number of 
cell surface-associated virulence factors, including cytoadhesive pili that mediate 
attachment to macrophages and epithelial cells (7, 10). 
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1.4 R. equi Interactions with Macrophages 
 
Bacterial uptake by macrophages is typically enhanced when the pathogen is 
complement-opsonized and internalized by the complement receptor CR3 (Mac-1). Mac-1 
has been identified as the primary receptor involved in bacterial recognition, and loss of 
Mac-1 significantly reduces bacterial binding (53). However, phagocytosis of R. equi by 
macrophages can occur in the absence of complement, possibly mediated by direct binding 
of the mannose receptor to the R. equi cell surface (39, 53). Typically following 
macrophage engulfment, the pathogen-containing phagosome fuses with lysosomes to 
form a phagolysosome. Within the phagolysosome, the combined action of a low pH (pH 
4-5), hydrolytic enzymes, and the production of reactive oxygen species (ROS) kills the 
pathogen (32, 51). However, this is not the case following phagocytosis of virulent R. equi. 
Similar to other intracellular pathogens, R. equi have evolved escape mechanisms to 
prevent phagolysosome maturation into late endocytic organelles (3, 23, 51, 53, 54). Within 
the RCV, VapA trafficks between subcellular compartments to prevent the proton- 
pumping vacuolar ATPase (v-ATPase) from joining and further acidifying the phagosome, 
thereby preventing phagolysosome maturation. These processes allow for uncontrolled 
intracellular R. equi replication, leading to necrosis of the macrophage (23, 53, 54). 
 
 
 
1.5 Disease Progression and Clinical Manifestation 
 
The most common clinical sign of R. equi infection is a lower respiratory tract 
disease characterized by coughing, fever, increased respiratory rate and effort, increased 
heart rate, and abnormal airway sounds (1, 24). Subclinical presentation includes mild 
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neutrophilic leukocytosis and hypofibrinogenaemia while more severe cases present with 
pyogranulomatous cavitating pneumonia and neutrophilia (1, 13, 27). In the early stages of 
disease, pulmonary lesions develop, and alveoli fill with neutrophils, macrophages, and 
giant cells, many of which contain R. equi. Ulcerative enteritis and osteomyelitis can result 
from ingestion of R. equi-contaminated sputum during pulmonary disease (24, 32). Due 
to its zoonotic capabilities, pathogenesis isn’t limited to equids. R. equi is a recognized 
opportunistic pathogen of pigs, goats, and even humans suffering from immune 
deficiencies (23, 32, 43). Consequently, clinical disease manifestation can differ between 
species. For example, experimentally infected mice develop liver and kidney abscessation 
that typically self-resolves due to the murine resistance to R. equi infection (8, 25, 32). 
Foals on endemic farms become infected early in life (30), with infection occurring 
within six weeks post-foaling, via inhalation of virulent R equi (18, 55). Recent studies 
have indicated that foals can become infected as early as one-week post-foaling (30, 39, 
44, 56, 57). Based on experimental intrabronchial challenge, the incubation period is 
between 9 days to 4 weeks, but this may differ in uncontrolled environments (39, 58). At 
the cellular level, R. equi infection results in macrophagic necrosis that is typically 
accompanied by pyogranulomatous inflammation that damages surrounding lung tissue (7, 
12, 43, 44). In severe cases, this may present as a chronic bronchopneumonia with 
abscessation and associated lymphadenitis and ulcerating enteritis (10, 12, 32, 43, 44). 
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1.6 Diagnosis and Natural Immunity 
 
Early diagnosis and prompt and improved antimicrobial therapy contributes to 
increased survival (7, 15, 18). However, disease burden is not an accurate representation 
of prevalence as clinical signs are delayed (7, 18). Early clinical signs consist of a mild 
fever, occasional cough, or slight increase in respiratory rate which is only apparent when 
the animal is stressed or exercised. While more clinical signs become apparent with disease 
progression, including cough, fever, lethargy and increased respiratory effort, the most 
common presentation is subclinical ultrasonographic evidence of pulmonary abscessation 
(6, 19, 31). 
Unfortunately, it is difficult to accurately characterize the burden of disease in foals 
as diagnosis at endemic farms is often presumptive. This is because veterinarians or farm 
managers eschew the use of the gold standard tracheobronchial aspiration (TBA) and lab 
testing in some or all foals due to the health risks, along with the time and physical effort 
required. Additionally, it is a costly procedure as findings should be supported by 
cytological evidence to reduce the likelihood of false-positive results due to the ubiquity 
of R. equi in the environment (28, 59, 60). As alternatives to TBA are lacking, diagnosis is 
typically based on signalment, clinical signs, and results of thoracic ultrasonography, of 
which the screening is becoming increasingly common at endemic farms to identify foals 
with pulmonary consolidation or abscess formation attributed to R. equi infection (22, 28, 
29). Thoracic ultrasonography allows visualization of the lateral pleural surface of the lung, 
and a presumptive diagnosis can be made by detection of pulmonary pathology such as 
lung abscessation. Additionally, the procedure is relatively quick for an individual foal and 
results are available immediately (6, 15, 19, 30). However, diagnosis is more reliably made 
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by bronchial brushings, percutaneous thoracic aspiration, or open lung biopsies during 
lobectomy, particularly as serological testing is inaccurate as R. equi antibodies are 
commonly present in the horse population resulting in the inability to distinguish between 
disease and exposure (28, 41, 61). 
Additionally, a combination of bacterial factors and host cell factors determines the 
success or failure of R. equi infection. Differences among horse populations can influence 
disease susceptibility as many foals on endemic farms don’t develop disease (18, 31, 41). 
Subpopulation predisposition to R. equi susceptibility may be influenced by the interaction 
between innate and adaptive immunity; however, this linkage is not yet clear (14, 27, 62- 
64). In concert with the lack of immunologic memory in newborn foals, there are a number 
of relative immunologic deficits that have been observed and postulated to account for the 
unique age-associated susceptibility of foals to rhodococcal pneumonia. Age-related 
deficiencies in R. equi-specific cytotoxic T lymphocyte (CTL) activity has been 
documented in 3 week-old foals (65). While the activity of CTLs improves by 6 weeks of 
age and becomes similar to that of healthy adult horses by 8 weeks of age, the time frame 
of CTL deficiency corresponds to foal susceptibility. Furthermore, antigen-presenting cells 
have a significantly reduced CD1 and MHC class II expression in foals than in horses (65- 
68). This reduces levels of antigen presentation and the subsequent acquired immune 
response required for bacterial clearance. Though R. equi would be quickly eliminated by 
neutrophils in adult horses, monocytes and macrophages are the most common R. equi 
reservoir in foals (32, 39). 
The degree of infection can also bias immunoglobulin (Ig) type and T helper cells 
(Th) (18, 41). For example, foals can produce an IgM and IgG response early in life, but 
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severely pneumonic foals primarily produce a predominant IgGT or IgGb immunoglobulin 
response which favors R. equi survival (18, 41). Antigen specific IgG plays an important 
role in opsonization to promote phagocytosis of the virulent R. equi; however, low antibody 
titers in foals may contribute to age-related susceptibility (69, 70). Cell-mediated 
mechanisms are thought to be the major means of immunity to R. equi and other 
intracellular pathogens (24). Naturally infected foals that overcome respiratory disease 
mount a Th1 immune response with IgG2a predominating, allowing for an ideal Th1:Th2 
ratio that ensures a balanced cytokine production. In infected foals, a Th2 cell-mediated 
response is considered to be detrimental and often associated with the development of 
clinical pneumonia (69-72). However, this mechanism of resistance is speculative and 
hasn’t been experimentally demonstrated in foals (39). In addition, R. equi susceptibility 
has been associated with defective IFN-g production in response to mitogens paired with a 
Th2 bias. However, deficient IL-4 production in response to stimulation with mitogen also 
suggests that polarization to a Th2 response is unlikely in neonatal foals (71-74). 
 
 
 
 
1.7 Prevention, Control and Treatment 
 
As many horse breeding farms exhibit endemic R. equi infection, prophylaxis may 
be the most effective approach in control. However, highly effective preventative measures 
are currently lacking (28, 41, 75, 76). The main focus of an effective strategy should 
involve environmental management, particularly practices that reduce the likelihood of 
inhaling contaminated air. This can be encouraged by providing outdoor housing on soil 
with high water holding capacity and by maintaining good pasture cover and preventing 
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fecal buildup in paddocks and yards to reduce R. equi exposure (76-78). Likewise, current 
aseptic methods such as disinfection of stables, decontamination of bedding material and 
quarantining of infected foals should not be abandoned (31, 79, 80). 
Currently, there are a number of challenges associated with combating R. equi 
infections. First, the increasing and widespread prevalence of antimicrobial resistance 
among R. equi isolates is fast ensuring the ineffectiveness of currently available treatments. 
A number of mechanisms contribute to R. equi multidrug resistance including the 
acquisition of a macrolide resistance gene, erm. A component of the TnRErm46, erm 
encodes an erythromycin-resistant methylase gene that is transmissible via a conjugative 
plasmid (26, 29, 38, 41). Additionally, antimicrobial intervention occurs either 
immediately following detection of pulmonary lesions following ultrasonography without 
confirming R. equi colonization, or after symptoms have appeared in the case of farms that 
forgo thoracic ultrasonography (9, 19, 81-83). Finally, the ability of R. equi to infect 
macrophages and replicate intracellularly ensures protected bacterial proliferation within 
host sites that are shielded from antibiotic intervention (23, 40, 41). Since the 1980’s, 
standard treatment recommendation for R. equi disease has been a combination of 
macrolides and rifampin. However, there continues to be increased documented instances 
of resistance to first line antibiotics, and there have also been adverse reactions associated 
with these therapies (22, 29, 41). Drug reactions have included partial anorexia, mild colitis 
and bruxism which usually resolve after temporary cessation of treatment. Ingestion of 
active macrolides due to coprophagic behavior can result in self-limiting diarrhea and C. 
difficile colitis in the mare of the treated foal due to macrolide-induced alteration of the 
intestinal flora (29, 84). Though alternative treatments are available, treatment can be 
13  
prolonged and expensive, and disease prevention is limited. Examples of alternative 
treatments include the transfusion of hyperimmune plasma which exhibits incomplete 
efficacy, and chemoprophylaxis which is inconsistently effective and may promote 
antimicrobial resistance (30, 57, 76, 85, 86). 
In recent years, newer macrolides have become available to replace the 
combination therapy and are better tolerated, require less frequent administration, and have 
a reduced frequency of adverse side effects (28, 29). However, we are still faced with the 
challenge of developing an effective vaccine that can overcome the relative immaturity of 
the naive neonatal immune system. There is also a need to determine immunologic 
correlates of protection, define limitations of foal immunity, and specify bacterial antigens 
that confer protective immunity (39, 41). 
 
 
 
 
1.8 Antibiotic Resistance 
 
Antimicrobial resistance is a pressing issue in both human and animal health that 
has resulted from a multitude of factors, including the unrestrained use of antibiotics (23, 
28). In the case of equine breeding farms, antimicrobial resistance has been amplified 
through the preemptive treatment of foals exhibiting lung lesions detected via thoracic 
ultrasonography. Additionally, it has been reported that there is minimal benefit associated 
with the treatment of foals displaying subclinical symptoms compared to those left 
untreated as disease resolution rates are comparable between treatment and control groups 
(19, 82, 83, 85, 87). 
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Multiple mechanisms of antibiotic resistance exist. For example, mechanisms of 
acquired macrolide resistance include ribosomal RNA (rRNA) methylation, active drug 
efflux, and enzymatic inactivation, with the two former mechanisms accounting for the 
majority of resistant bacterial isolates (22). rRNA methylation-based resistance occurs 
through nucleotide methylation within 16s rRNA which impairs binding of the 
antimicrobial to the 30s rRNA subunit (88). A specific example for R. equi is the presence 
of erm which imparts cross-resistance to macrolides (22). During active antibiotic efflux, 
members of the ATP binding cassette family or those from the major facilitator superfamily 
transporters pump anti-microbial agents out of the cell or cellular membrane, rescuing the 
function of bacterial ribosomes (22). Enzymatic inactivation of macrolides typically occurs 
in bacteria that don’t harbor known acquired macrolide resistance genes and is often 
associated with mutations in the V domain of the 23s rRNA genes and other genes coding 
the ribosomal proteins L4 and L22 (22). The combination of these mechanisms and the 
presence of antimicrobial resistance genes has led to the commonality of cross-resistance 
among macrolides. As a result, the development of new macrolides may not be beneficial 
due to the potential for pre-existing resistance mechanisms (10, 29). In the case of rifampin, 
increased resistance rates in R. equi has been confirmed by increases in the minimum 
inhibitory concentration (MIC) required for effective action. Rising rifampin resistance has 
been correlated to prolonged therapy and monotherapy as well as mass antimicrobial 
treatment of subclinically affected foals (22, 29). Sequencing of the R. equi genome has 
revealed many antimicrobial resistance genes, including a number of putative multi-drug 
resistance genes (22, 29). In addition to bacterial factors that confer antibiotic resistance, 
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poor eukaryotic cellular uptake can minimize the intracellular concentrations of 
antimicrobials, contributing to decreased effectiveness (22). 
 
 
 
 
1.9 Silver Nanoparticle Therapeutics 
 
The use of silver nanoparticles (AgNPs) as an antibacterial agent has been widely 
and historically documented, and nanoparticle compounds have been incorporated in 
various aspects of modern medicine (89-93). Various nanomaterials have been found to 
exhibit different modes of bacterial inactivation, showing promising efficacy as a new 
antimicrobial therapy. In some studies, the antibacterial effect of silver ions results from 
their release into the acidic lysosome (89-94). This allows AgNPs to react with thiol 
functional groups in nucleic acids and proteins to interfere with DNA replication and 
deactivate enzymatic functions, and also induces production of ROS that interfere with 
electron transport systems, inactivate enzymes, associate with and denature DNA, and 
disturb cell membrane transport (89-94). 
Currently, the antibacterial mechanism of AgNP compounds has not been fully 
elucidated due to Ag-NP dynamics (95, 96). Three proposed mechanisms of action suggest 
that (i) the silver ion is responsible for the antimicrobial activity while the nanoparticle 
component acts as a reservoir, (ii) the AgNP activity results from the physical disruption 
of the cell membrane or through production of ROS by the compound rather than silver 
ions, and/or (iii) a synergistic combination of physical disruption and interaction of free 
silver ions with the bacterial cell (95, 97-99). 
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In additional to bacterial viability, silver(I) complexes have been reported to display 
cytotoxicity toward various cell types, including macrophages (91, 92). Studies have 
demonstrated that phagocytic- and energy-dependent internalization of Ag complexes by 
macrophages may lead to toxicity (91, 92). Ag-toxicity may result from the binding of 
metal ions to disulfide bonds in the cytoplasm which induce deformities in protein structure 
and cell permeability following their incorporation into the plasma membrane (91, 92). 
This mechanism was dependent on the type of ligand linked to the silver ion and was 
suggested to disrupt hydrophilic and lipophilic interactions. The impact of silver ions on 
molecular and cellular structures varies among different complexes, with colloidal silver 
compounds used more frequently in treatment strategies compared to ionic silver 
compounds (100-103). The efficacy of AgNPs against R. equi viability and infectivity has 
not been demonstrated. Therefore, it is important to assess not only the antimicrobial 
effectivity of AgNPs against R. equi, but also to assess the effects of AgNP treatment in a 
variety of host cells. 
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CHAPTER 2. EXPERIMENTATION 
 
 
2.1 Purpose of the Study 
 
Antimicrobial resistance continues to be a pressing issue in human and equine 
medicine. Increased prevalence of antibiotic resistant R. equi isolates has been associated 
with mortality resulting from unresolved disease progression (15). Therefore, immediate 
action is required to identify alternate means to combat R. equi-induced 
bronchopneumonia. With the promising potential presented by AgNP-based therapeutics, 
the following study was undertaken to assess the effects of a commercially available silver 
compound as a treatment option against R. equi. We hypothesize that AgNP-based 
therapies will exert inhibitory effects against R. equi proliferation. Since the complex is 
available as a chitosan and chelated compound, both formulations were tested. As metal 
ion stability is dependent on ligand linkage, additional studies have been included to assess 
the safety of AgNPs in multiple cell types to rule out potential adverse effects. 
 
 
 
2.2 Materials and Methods 
 
2.2.1 Bacterial Growth Conditions 
 
The R. equi strain 103+ (104, 105) was stored as a frozen stock in 20% glycerol at 
 
-80°C and was streaked onto a brain heart infusion (BHI) plate prior to in vitro studies. To 
induce virulence gene expression, R. equi was inoculated into BHI broth culture and grown 
shaking in a rotatory shaker at 225 rpm for 24 hours. Following overnight growth, an 
optical density of 600nm (OD600) was obtained using the Thermo Scientific NanoDrop 
18  
OneC. Overnight cultures were diluted to an OD600 of 0.1 and aliquoted into 96-well U- 
bottom plates in preparation for treatment with silver nanoparticle complexes. 
 
 
 
 
2.2.2 Host Cell Growth Conditions 
 
Murine J774a.1 macrophage-like cells (ATCC) and equine pulmonary artery 
endothelial cells were grown in Dulbecco’s Modified Eagle’s Medium (Gibco) (DMEM) 
supplemented with 1% L-glutamine, 1% sodium pyruvate and 10% HyClone Fetal Bovine 
Serum (FBS). Cells were grown in a T-75 flask at 37°C in 5% CO2 to confluency (8.4 x 
106 cells). Cell monolayers were trypsinized and seeded into a 96-well plate in fresh 
DMEM (seeding density = 104 cells per well). The cells were allowed to adhere over 24 
hours at 37°C, 5% CO2 prior to experimentation. 
 
 
 
 
2.2.3 Assessment of Bacterial and Host Cell Viability 
 
To assess R. equi and the J774a.1 cell viability in the presence of silver nanoparticle 
complexes over time, bacterial and host cells were treated with fresh media containing 
either 100 parts per million1 (ppm) of a silver chitosan (chitosan-Ag) or chelated (chelated- 
Ag) complex before incubation at 37°C for six hours under continuous shaking conditions 
at 225 rpm. R. equi viability was determined by enumerating colony forming units per 
 
 
 
 
 
1 This dose was selected as both compounds were provided as 1000 ppm concentrates with no 
weight/volume ratio and no known treatment dose. 
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milliliter of culture (CFU/mL), while host cell viability was determined by cellular ATP 
content by Cell-Titer-Glo (Promega) at defined intervals. 
To determine the minimum dose at which the silver nanoparticle compounds were 
effective, R. equi, J774a.1 and equine pulmonary endothelial cells were incubated in fresh 
media containing two-fold serial dilutions of either chitosan-Ag or chelated-Ag to a final 
concentration ranging from 0 ppm to 100 ppm. The bacteria were incubated for six hours 
at 37°C under continuous shaking conditions at 225 rpm. Bacterial viability was 
determined by enumerating CFU/mL of the bacterial culture and comparing the number of 
viable bacteria to those obtained from an untreated control group. Eukaryotic cells were 
incubated for an hour at 37°C and cell viability was assessed by determining the cellular 
ATP content using CellTiter-Glo (Promega). 
 
 
 
 
2.2.4 Differentiating Host Cell Death by Necrosis and Apoptosis 
 
J774a.1 macrophage-like cells were grown to confluency and treated with fresh 
media containing varying concentrations either chitosan-Ag or chelated-Ag compounds, at 
two-fold serial dilutions ranging from 0 ppm to 12.5 ppm final concentration. The 
mechanism of cell death was determined by a luminescence- and fluorescence-based assay 
(RealTime-Glo, Annexin V Apoptosis and Necrosis Assay, Progema). In this assay, a 
luminescence-based reporter indicates phosphatidylserine translocation to the outer leaflet 
of the cell membrane during early apoptosis (measured using Relative Luminescence Units 
[RLU]) and a cell-impermeant pro-fluorescent dye measures necrosis (measured using 
Relative Fluorescence Units [RFU]). Total luminescence and fluorescence (excitation = 
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485l; emission = 528l) measurements were obtained every 4 minutes using the Synergy 
H1 plate reader (Biotek). 
 
 
 
2.3 Results 
 
2.3.1 Silver Nanoparticles as Antimicrobials Against R. equi 
 
To determine whether chitosan-Ag or chelated-Ag nanoparticle complexes impact 
 
R. equi viability, bacteria were grown in pure culture and treated with varying 
concentrations of either compound ranging from 0 ppm to 100 ppm at two-fold serial 
dilutions (106). Enumeration of colony forming units determined that both AgNPs 
exhibited modest bactericidal activity against R. equi at concentrations ranging from 1.6 
ppm to 12.5 ppm and included a marked decrease in viability over a range of 25 ppm to 
100 ppm (Fig. 1). 
By comparing the CFU of the treated samples to control (mock treated) samples, 
the percent log10 reduction of pathogen viability was calculated. At six hours post- 
treatment, treatment with 100 ppm chitosan-Ag complex resulted in a mean log10 reduction 
in viable R. equi by 98.87%, while treatment with 100 ppm of chelated-Ag complex 
resulted in a mean log10 reduction in viable R. equi by 99.98% (Table 1). These values 
correspond to a 2.2 log10 reduction in the number of viable R. equi treated with 100 ppm 
chitosan-Ag complex versus a 4.2 log10 reduction in the number of viable R. equi treated 
with 100 ppm chelated-Ag complex (Table 1). These data demonstrate that silver 
nanoparticle complexes significantly impact R. equi viability when bacteria are grown in 
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Figure 1 Effect of chitosan-Ag and chelated-Ag formulations on R. equi growth in pure 
culture. 
R. equi 103+ was grown overnight in shaking culture at 37°C prior to diluting to an 
optical density at 600 nm (OD600) of 0.1 in fresh media containing various concentrations 
of chitosan-Ag or chelated-Ag complexes. Bacteria were incubated for 6 h at 37°C under 
continuous shaking and numbers of viable R. equi were determined by enumerating colony 
forming units per milliliter (CFU/mL) of bacterial culture. Data represent the mean values 
± the standard error of the mean for a minimum of three biological replicate experiments. 
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Table 1 Bactericidal effect of chitosan-Ag and chelated-Ag on R. equi growth. 
 
 
 
 
 
 
2.3.2 Cellular Cytotoxicity of Silver Nanoparticle Antimicrobials 
 
Treatment of R. equi with either 100 ppm of chitosan-Ag compound or 100 ppm of 
chelated-Ag compound resulted in significant reduction in the number of viable cells 
within four hours as determined by CFU/mL enumeration (Fig. 2A). Under the same 
treatment conditions, host cell cytotoxicity was observed in murine J774a.1 macrophage- 
like cells (a surrogate for equine macrophages which are the replicative site during R. equi 
acute pulmonary infection). In the experimental conditions, host cell viability was 
significantly reduced within 30 minutes of exposure to either AgNP complex (Fig. 2B). 
Together, these data indicate that chitosan-Ag and chelated-Ag complexes exhibit cellular 
toxicity in both R. equi and host macrophage-like cells. 
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Figure 2 Effect of silver nanoparticle complexes on bacterial and host cell viability over 
time. 
(A) R. equi 103+ was grown overnight in shaking culture at 37°C prior to diluting 
to an OD600 of 0.1 in fresh media containing either 100 ppm chitosan-Ag or chelated-Ag 
complex. Bacteria were incubated for 6 h at 37°C under continuous shaking and numbers 
of viable R. equi were determined by enumerating CFU/mL of bacterial culture at the 
indicated time-points. (B) Murine macrophage-like cells (J774a.1) were grown to 
confluency and treated with fresh media containing either 100 ppm chitosan-Ag or 
chelated-Ag complex. Cell viability was assessed by determining the cellular ATP content 
at the indicated time-points using a luminescence-based assay (CellTiter-Glo, Promega). 
Cell viability is expressed as relative luminescence units (RLU) for each time point and is 
proportional to the level of cellular ATP. Graphs depict the mean ± the standard error of 
the mean for each time point and data represent at least three biological replicate 
experiments. 
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2.3.3 Lethality of Bacterial and Host Cells by Silver Nanoparticle Antimicrobials 
 
Dose-response curves were derived to determine the concertation at which either 
chitosan-Ag or chelated-Ag resulted in 50% lethality (LD50). An accurate dose-response 
curve for bactericidal activities against R. equi could not be derived due to the rate of 
bacterial replication versus the rate of bactericidal activity under the experimental 
conditions (data not shown). However, LD50 values for both chitosan-Ag and chelated-
Ag complexes were determined using macrophage-like cells (Fig. 3). Our studies indicate 
that by one-hour post-treatment, the majority of eukaryotic cells were killed by exposure to 
100 ppm silver nanoparticle complexes (Fig. 2B). At one-hour post-treatment, chitosan-
Ag complexes exhibited an LD50 of approximately 4 ppm, while chelated-Ag exhibited 
an LD50 of approximately 6 ppm (Fig. 3B). Increasing exposure time to AgNPs did not 
significantly alter LD50 concentrations (chitosan-Ag LD50 approximately 5 ppm; chelated- 
Ag complexes LD50 approximately 7 ppm) demonstrating that silver nanoparticle 
complexes rapidly exert cytotoxic effects (Fig. 3C-D). Together, these data indicate that 
chitosan-Ag and chelated-Ag complexes are lethal to host macrophage-like cells at 
concentrations that reduce R. equi growth (Fig. 2, Fig. 3). 
Due to the rate of macrophage toxicity and cell death at low concentrations of either 
AgNP, as well as the inherent kinetics of bacterial uptake into the host cell, we were unable 
to assess whether AgNPs disrupt R. equi internalization, intracellular replication, or 
intracellular survival. A Bio-Plex Pro Mouse Cytokine 8-Plex Immunoassay was used to 
determine production of pro-inflammatory cytokines by cultured murine macrophages 
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when exposed to either the chitosan-Ag or chelated Ag complexes. Cell culture 
supernatants were analyzed on a single multiplexed plate to simultaneously determine the 
concentration of the selected proinflammatory cytokines. Analysis of GM-CSF, IFN-γ, IL- 
1β, IL-2, IL-4, IL-5, IL-10, and TNF-α levels produced by J774a.1 cells exposed to various 
concentrations of either chitosan-Ag or chelated-Ag ranging from 1.6 ppm to 6.3 ppm were 
assessed after 6 hours of AgNP treatment. Compared to untreated controls, neither 
chitosan-Ag nor chelated-Ag induced appreciable production of murine pro-inflammatory 
cytokines (data not shown). Collectively, our data indicate that exposure to AgNP 
complexes induces cytotoxicity in R. equi and macrophage-like cells that serve as a 
replicative niche during acute pulmonary infection. 
 
 
 
 
 
Figure 3 Effect of chitosan-Ag and chelated-Ag complexes on macrophage viability. 
 
(A) Murine J774a.1 macrophage-like cells were grown to confluency and treated 
with fresh media containing various concentrations of either chitosan-Ag or chelated-Ag 
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complex (two-fold serial dilutions ranging from 0 ppm to 100 ppm). At 1 h post-treatment, 
cell viability was assessed by determining the cellular ATP content using a luminescence- 
based assay (CellTiter-Glo, Promega). Cell viability is expressed as RLU for each time 
point and is proportional to the level of cellular ATP. (B) LD50 values were calculated from 
the cell viability data in A via non-linear regression ([inhibitor] vs. response – variable 
slope/four parameter analysis). (C) J774a.1 cell viability and (D) LD50 determination from 
the data presented in C after 4 hours of exposure to the indicated concentration of chitosan- 
Ag or chelated-Ag complex. In A and C, dots indicate individual data points, bars indicate 
the mean value ± the standard error of the mean for each concentration. For all panels, data 
represent at least three biological replicate experiments. 
 
 
 
 
2.3.4 Impact of silver nanoparticle antimicrobials on equine endothelial cells. 
 
Equine endothelial cells line the surface of blood and lymphatic vessels and are 
thus present in the lung. Due to the cytotoxic effect of the AgNPs on the macrophage-like 
cells, the potential impact of chitosan-Ag and chelated-Ag compounds on equine 
endothelial cells was assessed. Equine pulmonary endothelial cells were treated with 
varying concentrations of either chitosan-Ag or chelated-Ag compounds, ranging from 0 
ppm to 100 ppm. We observed significant cytotoxic effects in equine pulmonary 
endothelial cultures treated with both silver nanoparticle complexes at final concentrations 
as low as 3.1 ppm (Fig. 4). Our studies also indicated that chelated-Ag complexes induced 
a greater degree of equine pulmonary endothelial cell death than chitosan-Ag complexes 
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(Fig. 4). In total, these data demonstrate that silver nanoparticle complexes induce rapid 
cell death in a variety of host and bacterial cells. 
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Figure 4 Effect of silver nanoparticle complexes on equine endothelial cell viability. 
 
(A) Equine endothelial cells were grown to confluency and treated with fresh media 
containing various concentrations of either chitosan-Ag or chelated-Ag complex (two-fold 
serial dilutions ranging from 0 ppm to 100 ppm). At 1 h post-treatment, cell viability was 
assessed by determining the cellular ATP content using a luminescence-based assay 
(CellTiter-Glo, Promega). Cell viability is expressed as RLU for each time point and is 
proportional to the level of cellular ATP. (B) Equine endothelial cell viability after 4 h of 
exposure to the indicated concentration of chelated-Ag complex. In A and B, dots indicate 
individual data points, bars indicate the mean value ± the standard error of the mean for 
each concentration. For all panels, data represent at least three biological replicate 
experiments. 
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2.3.5 Mechanism of host cell death 
 
We next sought to determine the mechanism by which silver nanoparticle 
compounds induce cytotoxic activity in host cells. For these studies, J774a.1 macrophage- 
like cells were grown to confluency and treated with two-fold serial dilutions of either 
chitosan-Ag or chelated-Ag compounds ranging from 0 ppm to 12.5 ppm final 
concentration. The maximum concentration of 12.5 ppm was chosen as rapid cytotoxicity 
had been observed at this concentration of either chitosan-Ag or chelated-Ag (Fig. 3). We 
analyzed mechanisms of cell death using an Annexin V Apoptosis and Necrosis Assay 
(RealTime-Glo, Promega). Using this assay, we determined that AgNP-induced cell death 
results from rapid apoptosis and secondary necrosis. At all tested concentrations, 
fluorescence (propidium iodide staining), and luminescence signals (corresponding to 
detection of phosphatidyl serine translocation to the outer leaflet of the cell following 
flippase inactivation in early apoptosis) were observed (Figs. 5-6). Interestingly, a 
concentration of ~2 ppm of either chitosan-Ag or chelated-Ag induced cellular necrosis, 
which occurred within 30 minutes, similar to our previous data demonstrating silver 
nanoparticle-induced cell death (Fig. 2B, Fig. 5, Fig. 6). 
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Figure 5 Mechanism of cellular death by chitosan-Ag. 
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(A-E) Murine J774a.1 macrophage-like cells were grown to confluency and treated 
with fresh media containing various concentrations of chitosan-Ag (two-fold serial 
dilutions ranging from 0 ppm to 12.5 ppm). Immediately following treatment, mechanism 
of cellular death was assessed by using a luminescence and fluorescence-based assay 
(RealTime-Glo, Annexin V Apoptosis and Necrosis Assay [Promega]). 
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Figure 6 Mechanism of cellular death by chelated-Ag. 
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(A-E) Murine J774a.1 macrophage-like cells were grown to confluency and 
treated with fresh media containing various concentrations of chelated-Ag (two-fold 
serial dilutions ranging from 0 ppm to 12.5 ppm). Immediately following treatment, 
mechanism of cellular death was assessed by using a luminescence and fluorescence-
based assay (RealTime-Glo, Annexin V Apoptosis and Necrosis Assay [Promega]). 
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CHAPTER 3. DISCUSSION 
 
 
With reports of macrolide resistance steadily increasing in multiple bacterial 
species over the last few decades, research has shifted focus to the development of novel 
methods of disease prevention (107-110). R. equi is not an exception to this, and current 
research aims to identify potential targets for novel antibacterial production. Exploring the 
therapeutic potential of currently available antibacterial compounds as possible treatment 
alternatives also serves an important role in the race against antimicrobial resistance, 
particularly given the selective pressure resulting from unsuccessful and inappropriate 
treatment regimens (30, 38, 57, 76). Therefore, the purpose of this study was to assess the 
capacity of silver nanoparticle antimicrobials to impact R. equi viability and host cell 
cytotoxicity. 
The antimicrobial activity of silver nanoparticles against Gram-positive and Gram- 
negative bacteria has been analyzed previously, especially that of chitosan-silver 
complexes (111-114). Consistent with previous reports, our study demonstrated a reduction 
in R. equi growth in pure culture when treated with varying concentrations of either 
chitosan-Ag or chelated-Ag compounds. Our results also determined that treatment with 
the chelated-Ag complex inhibited R. equi growth in pure culture to an extent that exceeded 
the effects of chitosan-Ag complexes at the same concentrations (Fig. 1). For both silver 
nanoparticle complexes, a concentration of approximately 3 ppm achieved a reduction in 
R. equi viability by more than 90% log10 (Fig. 1, Table 1). The bacterial toxicity of 
chitosan-based AgNPs has previously been attributed to an increase in oxidative stress and 
the production of pores on the cell wall, with the mechanism appearing to be dependent on 
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the constitution, charge, and size of silver nanoparticle compounds (90, 93, 103, 111-115). 
Based on previous studies, we hypothesize that the chelated-Ag compound exerts 
antibacterial activity by decreasing osmotic stability of bacterial cells due to charge 
interactions between the cell wall and silver(I) ions released from the compound. In the 
eukaryotic cell, we hypothesize that chelated-Ag compounds exert cytotoxic effects 
through the excessive production of ROS that interact and interfere with histone-like 
nucleoid structuring proteins (115-120). 
While the observation that the chitosan-Ag and chelated-Ag complexes were 
effective against extracellular bacteria, R. equi, like Mycobacteria, parasitize macrophages 
as a means of using the host cell as a barrier for protective replication (7, 10, 53, 121). 
Therefore, effective antimicrobial activity against intracellular bacteria is required to 
ensure the probability of silver nanoparticles to be used as an alternative treatment against 
R. equi (18, 25, 32). When assessing the effect of silver nanoparticle compounds at 100 
ppm, our data demonstrated that R. equi viability was significantly reduced within four 
hours of exposure to either chitosan- or chelated-conjugated silver complexes (Fig. 2A). 
This observation supports previous studies that AgNPs impact intracellular bacteria; 
however, whether the time-frame of AgNP-induced R. equi toxicity in the current study is 
similar to previously reported toxicity levels is unknown, as silver-mediated toxicity can 
be impacted by composition and size of the compound, the dose used, and the bacterial 
species (122-124). Remarkably, the same dosage used to impact R. equi viability also 
induced rapid host cell death of macrophage-like cells within 30 minutes of treatment (Fig. 
2). This raised question as to whether there is an optimal concentration of AgNP complexes 
that ensures cytotoxicity against R. equi without exerting adverse consequences to host 
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cells. Our findings determined that the lethal dose required to achieve a minimal 90% log10 
reduction in R. equi (~3 ppm) did not significantly differ from the observed LD50 of 
macrophage-like cells when treated with chitosan-Ag (~4-5 ppm) or chelated-Ag (~5-6 
ppm) (Fig. 2B, Table 1). Our results demonstrate that cytotoxicity induced by the tested 
silver nanoparticle compounds is comparable across multiple cell types, supporting 
previous work (91, 92, 118, 125, 126). Considering that antibacterial properties of AgNPs 
can result from the release of silver(I) ions into the lysosome, it is possible that the host 
cells are affected in a similar way to the bacterial cells, whereby silver ions interfere with 
disulfide bonds, resulting in altered protein structure and permeability of the cell (89-94). 
The functionality of AgNPs may also be enhanced by macrophage phagocytic capabilities. 
However, due to the rate of macrophage cell death at low chitosan-Ag or chelated-Ag 
complexes concentrations, as well as the inherent kinetics of bacterial uptake into the host 
cell, we were unable to analyze whether either silver nanoparticle complex effects R. equi 
internalization, intracellular replication, or intracellular survival. 
The cytotoxic effects of the silver nanoparticle antimicrobials against murine 
macrophage-like cells raised the question as to whether additional host cell types were 
susceptible to cytotoxic effects. Therefore, we analyzed the effects of the silver compounds 
on equine pulmonary endothelial cells. Our studies determined that reduction in the 
viability of equine pulmonary endothelial cells exposed to either compound was similar to 
that exhibited by the macrophage-like cells (Fig. 3, Fig. 4). In contrast to the non-selective 
cytotoxicity demonstrated by our study, Radko et al. previously demonstrated the 
capability of silver(I) complexes to display selective cytotoxicity toward various cell types 
(91). Cytotoxic effects induced by silver(I) complexes were dictated by the type of ligand 
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linked to the silver ion and were suggested to result from nanoparticle complex stability 
(101). This selective cytotoxicity has also been suggested to result from the reactivity of 
silver(I) ions to molecular and cellular structures (100). Additionally, some studies have 
praised the relative safety of AgNPs when used as antimicrobials within the environment 
and some animal hosts (125-129). Previous reports focused on AgNP-induced macrophage 
toxicity raised safety concerns about the use of AgNPs, and suggested that the small size 
of the nanoparticles could cause numerous perturbations of host cells (102, 103, 118). 
Thus, more research will be required to evaluate the safety of using silver nanoparticles 
in agriculture, medicine, and food (130-132). In the current study, proprietary 
manufacturing details of the silver nanoparticle compounds were not provided. Therefore, 
we were unable to conduct studies to determine whether non-AgNP components of the 
formulation induced bacterial or host cell cytotoxicity. In addition, the in vivo stability of 
the assayed silver nanoparticle complexes is unknown, and therefore, we were unable to 
deduce whether free- roaming or liberated silver(I) ions could be responsible for the 
observed cytotoxic and bactericidal effects. 
Though previous studies have described adverse effects associated with silver 
nanoparticle compounds in macrophages, cell viability studies have not been conducted 
using chitosan- or chelated-conjugated silver compounds (102, 103). Using an assay 
designed to discriminate between two mechanisms of eukaryotic cell death, we were able 
to determine that both chelated and chitosan AgNP complexes induced toxicity of 
macrophage-like cells via both necrotic and apoptotic pathways (Fig. 5, Fig. 6). More 
interestingly, only ~2 ppm of either compound was sufficient to induce cell death. 
Considering the rapid cytotoxicity induced by low AgNP concentrations, particularly when 
37  
compared to dose required to perturb R. equi viability, the use of either compound as a 
treatment option for rhodococcal disease could lead to host cell damage. However, the 
analyzed silver nanoparticle formulations may be optimized for treating R. equi disease by 
altering the AgNP composition, concentration, and/or particle size. 
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CHAPTER 4. CONCLUSION 
 
 
Collectively, our studies indicate that chitosan-Ag and chelated-Ag compounds 
exhibit cytotoxicity against virulent R. equi and host cells, including murine macrophage- 
like cells and equine pulmonary endothelial cells. Using an immortalized cell line, we were 
able to determine that AgNP-induced cytotoxicity results from rapid apoptosis and 
secondary necrosis. Future studies will focus on resolving mechanisms of AgNP toxicity 
in R. equi and will determine whether AgNPs exert similar effects on primary equine 
macrophages. Furthermore, additional in vivo experimentation will be required to 
determine if our in vitro results correlate to equine infection models. Finally, additional 
experimentation is required to better understand the mechanisms underlying the silver 
nanoparticle-induced necrosis in host cells. 
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